EMA Withdrawn: Riprazo (aliskiren) — Novartis Europharm Ltd.

View source ↗

Summary

EMA has withdrawn Riprazo (aliskiren) from the market in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Riprazo (aliskiren)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 17/08/2012